Goals of chronic obstructive pulmonary disease management: a focused review for clinicians.

Advanced Search

Sairam Raghavan, Umur Hatipoğlu, Loutfi S Aboussouan

Author Information

Sairam Raghavan: Integrated Hospital-Care Institute, Department of Pulmonary Medicine, Cleveland Clinic, Cleveland, Ohio, USA.

PMID: 39620703 DOI: 10.1097/MCP.0000000000001144

PURPOSE OF REVIEW: The diagnosis of chronic obstructive pulmonary disease (COPD) encompasses heterogeneous pathophysiological mechanisms which can shape an individual patient's experience. This paper reviews available therapeutic options for the clinician intending to individualize care toward patient goals.
RECENT FINDINGS: The contemporary targeted interventions for COPD include the novel phosphodiesterase inhibitor ensifentrine, the interleukin-4 receptor (IL4R alpha subunit) antibody dupilumab, augmentation therapy for alpha-1 antitrypsin deficiency. Other interventions promoting physical and mental well being include re-envisioned pulmonary rehabilitation, self-management, targeting of comorbidities such as sarcopenia, and virtual health coaching interventions to expand patient access. Opioids did not relieve dyspnea and did not change total step count.
SUMMARY: Advances in precision therapy are complemented by the discovery of novel pathophysiology pathways and behavioral and rehabilitation interventions as a holistic view of COPD management emerges. The management of COPD continues to evolve with new tools including precision medicine and individualized care. Comorbidities remain important determinants of health, yet their prevalence and impact are underestimated.

Agusti A, Celli BR, Criner GJ, et al. Global initiative for chronic obstructive lung disease 2023 report: GOLD Executive Summary. Am J Respir Crit Care Med 2023; 207:819–837.

Diab N, Gershon AS, Sin DD, et al. Underdiagnosis and overdiagnosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2018; 198:1130–1139.

Anzueto A, Rogers S, Donato B, et al. Treatment patterns in patients with newly diagnosed COPD in the USA. BMC Pulm Med 2024; 24:395.

Montiel AM, Ruiz-Esteban P, Del Rio AD, et al. Differences in cardiovascular risk and health-related quality of life in COPD patients according to clinical phenotype. Sci Rep 2024; 14:9687.

David B, Bafadhel M, Koenderman L, De Soyza A. Eosinophilic inflammation in COPD: from an inflammatory marker to a treatable trait. Thorax 2021; 76:188–195.

Schrijver J, Lenferink A, Brusse-Keizer M, et al. Self-management interventions for people with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2022; 1:CD002990.

Jenkins AR, Burtin C, Camp PG, et al. Do pulmonary rehabilitation programmes improve outcomes in patients with COPD posthospital discharge for exacerbation: a systematic review and meta-analysis. Thorax 2024; 79:438–447.

Benzo R, Vickers K, Novotny PJ, et al. Health coaching and chronic obstructive pulmonary disease rehospitalization. a randomized study. Am J Respir Crit Care Med 2016; 194:672–680.

Mahler DA, Kerwin E, Ayers T, et al. FLIGHT1 and FLIGHT2: efficacy and safety of QVA149 (indacaterol/glycopyrrolate) versus its monocomponents and placebo in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2015; 192:1068–1079.

Hanania NA, Mannino DM, Criner GJ, et al. Effect of age on the efficacy and safety of once-daily single-inhaler triple-therapy fluticasone furoate/umeclidinium/vilanterol in patients with COPD: a post hoc analysis of the informing the pathway of COPD treatment trial. Chest 2021; 159:985–995.

Tabberer M, Jones CE, Kilbride S, et al. Single-inhaler triple therapy and health-related quality of life in COPD: the IMPACT Study. Adv Ther 2020; 37:3775–3790.

Milara J, Navarro A, Almudever P, et al. Oxidative stress-induced glucocorticoid resistance is prevented by dual PDE3/PDE4 inhibition in human alveolar macrophages. Clin Exp Allergy 2011; 41:535–546.

Franciosi LG, Diamant Z, Banner KH, et al. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials. Lancet Respir Med 2013; 1:714–727.

Singh D. A new treatment for chronic obstructive pulmonary disease: ensifentrine moves closer. Am J Respir Crit Care Med 2023; 208:344–346.

Anzueto A, Barjaktarevic IZ, Siler TM, et al. Ensifentrine, a novel phosphodiesterase 3 and 4 inhibitor for the treatment of chronic obstructive pulmonary disease: randomized, double-blind, placebo-controlled, multicenter Phase III trials (the ENHANCE trials). Am J Respir Crit Care Med 2023; 208:406–416.

Janjua S, Fortescue R, Poole P. Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2020; 5:CD002309.

Ekstrom M, Ferreira D, Chang S, et al. Effect of regular, low-dose, extended-release morphine on chronic breathlessness in chronic obstructive pulmonary disease: the BEAMS Randomized Clinical Trial. JAMA 2022; 328:2022–2032.

Schwartzstein RM. Dyspnea - when a sensation becomes a symptom. JAMA 2022; 328:2014–2015.

Zanaboni P, Dinesen B, Hoaas H, et al. Long-term telerehabilitation or unsupervised training at home for patients with chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med 2023; 207:865–875.

Simon S, Joean O, Welte T, Rademacher J. The role of vaccination in COPD: influenza, SARS-CoV-2, pneumococcus, pertussis, RSV and varicella zoster virus. Eur Respir Rev 2023; 32:230034.

Bao W, Li Y, Wang T, et al. Effects of influenza vaccination on clinical outcomes of chronic obstructive pulmonary disease: a systematic review and meta-analysis. Ageing Res Rev 2021; 68:101337.

Global Initiative for Chronic Obstructive Pulmonary Disease. 2024 report. https://goldcopd.org/2024-gold-report .

Nagata K, Horie T, Chohnabayashi N, et al. Home high-flow nasal cannula oxygen therapy for stable hypercapnic COPD: a randomized clinical trial. Am J Respir Crit Care Med 2022; 206:1326–1335.

Hansel NN, Putcha N, Woo H, et al. Randomized clinical trial of air cleaners to improve indoor air quality and chronic obstructive pulmonary disease health: results of the CLEAN AIR Study. Am J Respir Crit Care Med 2022; 205:421–430.

Herath SC, Normansell R, Maisey S, Poole P. Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev 2018; 10:CD009764.

Ahmadian S, Sin DD, Lynd L, et al. Benefit-harm analysis of azithromycin for the prevention of acute exacerbations of chronic obstructive pulmonary disease. Thorax 2022; 77:1079–1087.

Ahmadian S, Johnson KM, Ho JK, et al. A cost-effectiveness analysis of azithromycin for the prevention of acute exacerbations of chronic obstructive pulmonary disease. Ann Am Thorac Soc 2023; 20:1735–1742.

Celli BR, Anderson JA, Cowans NJ, et al. Pharmacotherapy and lung function decline in patients with chronic obstructive pulmonary disease. A systematic review. Am J Respir Crit Care Med 2021; 203:689–698.

Suissa S. Number needed to treat: enigmatic results for exacerbations in COPD. Eur Respir J 2015; 45:875–878.

Suissa S. Number needed to treat in COPD: exacerbations versus pneumonias. Thorax 2013; 68:540–543.

Oba Y, Keeney E, Ghatehorde N, Dias S. Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis. Cochrane Database Syst Rev 2018; 12:CD012620.

Arnold MJ. Treatment of chronic obstructive pulmonary disease: guidelines from the American Thoracic Society. Am Fam Physician 2021; 104:102–103.

Axson EL, Lewis A, Potts J, et al. Inhaled therapies for chronic obstructive pulmonary disease: a systematic review and meta-analysis. BMJ Open 2020; 10:e036455.

Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med 2018; 378:1671–1680.

Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med 2020; 383:35–48.

Nici L, Mammen MJ, Charbek E, et al. Pharmacologic management of chronic obstructive pulmonary disease. An official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med 2020; 201:e56–e69.

Poole P, Sathananthan K, Fortescue R. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2019; 5:CD001287.

Rogliani P, Matera MG, Page C, et al. Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine. Respir Res 2019; 20:104.

Rabe KF, Rennard S, Martinez FJ, et al. Targeting type 2 inflammation and epithelial alarmins in chronic obstructive pulmonary disease: a biologics outlook. Am J Respir Crit Care Med 2023; 208:395–405.

Brightling CE, Bleecker ER, Panettieri RA Jr, et al. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. Lancet Respir Med 2014; 2:891–901.

Pavord ID, Chanez P, Criner GJ, et al. Mepolizumab for eosinophilic chronic obstructive pulmonary disease. N Engl J Med 2017; 377:1613–1629.

Criner GJ, Celli BR, Brightling CE, et al. Benralizumab for the prevention of COPD exacerbations. N Engl J Med 2019; 381:1023–1034.

Bhatt SP, Rabe KF, Hanania NA, et al. Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts. N Engl J Med 2023; 389:205–214.

Bhatt SP, Rabe KF, Hanania NA, et al. Dupilumab for COPD with blood eosinophil evidence of type 2 inflammation. N Engl J Med 2024; 390:2274–2283.

Wedzicha JA, Calverley PM, Rabe KF. Roflumilast: a review of its use in the treatment of COPD. Int J Chron Obstruct Pulmon Dis 2016; 11:81–90.

Anthonisen NR, Skeans MA, Wise RA, et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005; 142:233–239.

Doo JH, Kim SM, Park YJ, et al. Smoking cessation after diagnosis of COPD is associated with lower all-cause and cause-specific mortality: a nationwide population-based cohort study of South Korean men. BMC Pulm Med 2023; 23:237.

Mintz M, Barjaktarevic I, Mahler DA, et al. Reducing the risk of mortality in chronic obstructive pulmonary disease with pharmacotherapy: a narrative review. Mayo Clin Proc 2023; 98:301–315.

Qin R, Liu Z, Cheng AQ, et al. Efficacy of varenicline or bupropion and its association with nicotine metabolite ratio among smokers with COPD. Respirology 2024; 29:479–488.

Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet 1981; 1:681–686.

Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med 1980; 93:391–398.

Lacasse Y, Maltais F. When and when not to prescribe home oxygen in COPD. Arch Bronconeumol 2023; 59:350–351.

Albert RK, Au DH, et alLong-Term Oxygen Treatment Trial Research Group. A randomized trial of long-term oxygen for COPD with moderate desaturation. N Engl J Med 2016; 375:1617–1627.

Ekstrom M, Andersson A, Papadopoulos S, et al. Long-term oxygen therapy for 24 or 15 hours per day in severe hypoxemia. N Engl J Med 2024; 391:977–988.

Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356:775–789.

Lipson DA, Crim C, Criner GJ, et al. Reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2020; 201:1508–1516.

Martinez FJ, Rabe KF, Ferguson GT, et al. Reduced all-cause mortality in the ETHOS trial of budesonide/glycopyrrolate/formoterol for chronic obstructive pulmonary disease. a randomized, double-blind, multicenter, parallel-group study. Am J Respir Crit Care Med 2021; 203:553–564.

Suissa S. Perplexing mortality data from triple therapy trials in COPD. Lancet Respir Med 2021; 9:684–685.

Halpin DMG, Martinez FJ. Pharmacotherapy and mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2022; 206:1201–1207.

van Geffen WH, Tan DJ, Walters JA, Walters EH. Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2023; 12:CD011600.

Chapman KR, Burdon JG, Piitulainen E, et al. Intravenous augmentation treatment and lung density in severe alpha1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Lancet 2015; 386:360–368.

McElvaney NG, Burdon J, Holmes M, et al. Long-term efficacy and safety of alpha1 proteinase inhibitor treatment for emphysema caused by severe alpha1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE). Lancet Respir Med 2017; 5:51–60.

Fraughen DD, Ghosh AJ, Hobbs BD, et al. Augmentation therapy for severe alpha-1 antitrypsin deficiency improves survival and is decoupled from spirometric decline-a multinational registry analysis. Am J Respir Crit Care Med 2023; 208:964–974.

Hatipoglu U, Aboussouan LS. Chronic hypercapnic respiratory failure and noninvasive ventilation in people with chronic obstructive pulmonary disease. BMJ Med 2022; 1:e000146.

Kohnlein T, Windisch W, Kohler D, et al. Noninvasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: a prospective, multicentre, randomised, controlled clinical trial. Lancet Respir Med 2014; 2:698–705.

Murphy PB, Rehal S, Arbane G, et al. Effect of home noninvasive ventilation with oxygen therapy vs oxygen therapy alone on hospital readmission or death after an acute COPD exacerbation: a randomized clinical trial. JAMA 2017; 317:2177–2186.

Raveling T, Vonk JM, Hill NS, et al. Home noninvasive ventilation in severe COPD: in whom does it work and how? ERJ Open Res 2024; 10.

Naunheim KS, Wood DE, Mohsenifar Z, et al. Long-term follow-up of patients receiving lung-volume-reduction surgery versus medical therapy for severe emphysema by the National Emphysema Treatment Trial Research Group. Ann Thorac Surg 2006; 82:431–443.

Hartman JE, Welling JBA, Klooster K, et al. Survival in COPD patients treated with bronchoscopic lung volume reduction. Respir Med 2022; 196:106825.

Labarca G, Uribe JP, Pacheco C, et al. Bronchoscopic lung volume reduction with endobronchial zephyr valves for severe emphysema: a systematic review and meta-analysis. Respiration 2019; 98:268–278.

Cote CG, Celli BR. BODE index: a new tool to stage and monitor progression of chronic obstructive pulmonary disease. Pneumonol Alergol Pol 2009; 77:305–313.

Weill D, Benden C, Corris PA, et al. A consensus document for the selection of lung transplant candidates: 2014--an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2015; 34:1–15.

Bleisch B, Schuurmans MM, Klaghofer R, et al. Health-related quality of life and stress-related posttransplant trajectories of lung transplant recipients: a three-year follow-up of the Swiss Transplant Cohort Study. Swiss Med Wkly 2019; 149:w20019.

Perch M, Hayes D Jr, Cherikh WS, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-ninth adult lung transplantation report-2022; focus on lung transplant recipients with chronic obstructive pulmonary disease. J Heart Lung Transplant 2022; 41:1335–1347.

Lindenauer PK, Stefan MS, Pekow PS, et al. Association between initiation of pulmonary rehabilitation after hospitalization for COPD and 1-year survival among medicare beneficiaries. JAMA 2020; 323:1813–1823.

Chen H, Luo X, Du Y, et al. Association between chronic obstructive pulmonary disease and cardiovascular disease in adults aged 40 years and above: data from NHANES 2013-2018. BMC Pulm Med 2023; 23:318.

Sa-Sousa A, Rodrigues C, Jacome C, et al. Cardiovascular risk in patients with chronic obstructive pulmonary disease: a systematic review. J Clin Med 2024; 13:5173.

Maclagan LC, Croxford R, Chu A, et al. Quantifying COPD as a risk factor for cardiac disease in a primary prevention cohort. Eur Respir J 2023; 62:2202364.

Rabe KF, Hurst JR, Suissa S. Cardiovascular disease and COPD: dangerous liaisons? Eur Respir Rev 2018; 27:180057.

LaFon DC, Helgeson ES, Lindberg S, et al. beta-Blocker use and clinical outcomes in patients with COPD following acute myocardial infarction. JAMA Netw Open 2024; 7:e247535.

Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011; 365:395–409.

Krist AH, Davidson KW, Mangione CM, et al. Screening for lung cancer: US Preventive Services Task Force recommendation statement. JAMA 2021; 325:962–970.

de Blasio F, Di Gregorio A, de Blasio F, et al. Malnutrition and sarcopenia assessment in patients with chronic obstructive pulmonary disease according to international diagnostic criteria, and evaluation of raw BIA variables. Respir Med 2018; 134:1–5.

Liu H, Song J, Wang Z, et al. Investigation of nutrition status and analysis of 180-day readmission factors in elderly hospitalized patients with COPD. Aging Clin Exp Res 2024; 36:155.

Conway V, Hukins C, Sharp S, Collins PF. Nutritional support in malnourished outpatients with chronic obstructive pulmonary disease (COPD): a randomized controlled pilot study. Nutrients 2024; 16:1696.

Ferreira IM, Brooks D, White J, Goldstein R. Nutritional supplementation for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; 12:CD000998.

Rahi MS, Thilagar B, Balaji S, et al. The impact of anxiety and depression in chronic obstructive pulmonary disease. Adv Respir Med 2023; 91:123–134.

Wang J, Willis K, Barson E, Smallwood N. The complexity of mental healthcare for people with COPD: a qualitative study of clinicians’ perspectives. NPJ Prim Care Respir Med 2021; 31:40.

Keeratichananont W, Kaenmuang P, Geater SL, et al. Prevalence, associated factors, and clinical consequences of metabolic syndrome in chronic obstructive pulmonary disease patients: a 5-year prospective observational study. Ther Adv Respir Dis 2023; 17:17534666231167342.

Chan SMH, Selemidis S, Bozinovski S, Vlahos R. Pathobiological mechanisms underlying metabolic syndrome (MetS) in chronic obstructive pulmonary disease (COPD): clinical significance and therapeutic strategies. Pharmacol Ther 2019; 198:160–188.

Fekete M, Szollosi G, Tarantini S, et al. Metabolic syndrome in patients with COPD: Causes and pathophysiological consequences. Physiol Int 2022; 109:90–105.

Noh E, Jeong H, Cho IS, et al. Risk of cardiovascular events associated with chronic obstructive pulmonary disease and/or metabolic syndrome: a large-scale nationwide population-based cohort study. Int J Chron Obstruct Pulmon Dis 2024; 19:1447–1456.

Shawon MS, Perret JL, Senaratna CV, et al. Current evidence on prevalence and clinical outcomes of co-morbid obstructive sleep apnea and chronic obstructive pulmonary disease: a systematic review. Sleep Med Rev 2017; 32:58–68.

Kendzerska T, Leung RS, Aaron SD, et al. Cardiovascular outcomes and all-cause mortality in patients with obstructive sleep apnea and chronic obstructive pulmonary disease (overlap syndrome). Ann Am Thorac Soc 2019; 16:71–81.

Sterling KL, Pepin JL, Linde-Zwirble W, et al. Impact of positive airway pressure therapy adherence on outcomes in patients with obstructive sleep apnea and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2022; 206:197–205.

Chen YW, Ramsook AH, Coxson HO, et al. Prevalence and risk factors for osteoporosis in individuals with COPD: a systematic review and meta-analysis. Chest 2019; 156:1092–1110.

Inoue D, Inoue R. Mechanisms of osteoporosis associated with chronic obstructive pulmonary disease. J Bone Miner Metab 2024; 42:428–437.

Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019; 48:16–31.

Yu Z, He J, Chen Y, et al. Chronic obstructive pulmonary disease as a risk factor for sarcopenia: a systematic review and meta-analysis. PLoS One 2024; 19:e0300730.

Benz E, Trajanoska K, Lahousse L, et al. Sarcopenia in COPD: a systematic review and meta-analysis. Eur Respir Rev 2019; 28:190049.

Gomez-Martinez M, Rodriguez-Garcia W, Gonzalez-Islas D, et al. Impact of body composition and sarcopenia on mortality in chronic obstructive pulmonary disease patients. J Clin Med 2023; 12:1321.

Martinez-Luna N, Orea-Tejeda A, Gonzalez-Islas D, et al. Association between body composition, sarcopenia and pulmonary function in chronic obstructive pulmonary disease. BMC Pulm Med 2022; 22:106.

Sepulveda-Loyola W, Osadnik C, Phu S, et al. Diagnosis, prevalence, and clinical impact of sarcopenia in COPD: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle 2020; 11:1164–1176.

Huang WJ, Ko CY. Systematic review and meta-analysis of nutrient supplements for treating sarcopenia in people with chronic obstructive pulmonary disease. Aging Clin Exp Res 2024; 36:69.

Humans

Pulmonary Disease, Chronic Obstructive

Precision Medicine

Comorbidity

Journal Article Review

OpenLB
Open Library of Bioscience